DEFA14A: Sun Pharma to Acquire Checkpoint Therapeutics for Up to $416 Million, Bolstering Onco-Derm Franchise

Sun Pharmaceutical Industries will acquire Checkpoint Therapeutics for an upfront cash payment of $4.10 per share plus a contingent value right of up to $0.70 per share, potentially reaching a total transaction value of $416 million.

Summary

• Sun Pharmaceutical Industries is set to acquire Checkpoint Therapeutics, a commercial-stage immunotherapy and targeted oncology company.
• The acquisition includes UNLOXCYT (cosibelimab-ipdl), an FDA-approved treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC).
• Checkpoint stockholders will receive $4.10 per share in cash upfront, plus a contingent value right (CVR) of up to $0.70 per share.
• The CVR is contingent upon cosibelimab receiving approval in the European Union before certain deadlines.
• The upfront cash payment represents a 66.0% premium to Checkpoint's closing share price on March 7, 2025.
• The total transaction value could reach approximately $416 million.
• Fortress Biotech, Checkpoint's controlling stockholder, has agreed to a royalty agreement based on future sales of cosibelimab.
• The transaction is expected to close in the second calendar quarter of 2025, pending stockholder and regulatory approvals.
• For the nine-month period ending September 2024, Checkpoint reported $0.04 million in revenue and a net loss of $27.3 million.
• As of September 30, 2024, Checkpoint had a cash balance of $4.7 million, outstanding accounts payable and accrued expenses of $15.6 million, and outstanding accounts payable and accrued expenses related party of $2.0 million.

Sentiment

Score: 8

Explanation: The sentiment is positive due to the acquisition by a larger company, providing financial stability and growth opportunities. The upfront premium and potential CVR further contribute to the positive outlook.

Positives

• Sun Pharma gains an FDA-approved anti-PD-L1 treatment, UNLOXCYT, for advanced cSCC.
• Checkpoint stockholders receive a significant premium for their shares.
• The CVR provides potential for additional upside if cosibelimab is approved in the EU.
• Sun Pharma's global presence could accelerate patient access to UNLOXCYT.
• Fortress Biotech secures a royalty stream from future cosibelimab sales.

Negatives

• Checkpoint reported a net loss of $27.3 million for the nine-month period ending September 2024.
• Checkpoint had a relatively low cash balance of $4.7 million as of September 30, 2024.
• The CVR payment is contingent and may not be realized if EU approval is not obtained.

Risks

• The transaction is subject to customary closing conditions, including regulatory and stockholder approvals.
• The CVR payment is contingent on future regulatory approval, which is not guaranteed.
• The integration of Checkpoint's operations into Sun Pharma may present challenges.
• The market for cSCC treatments is competitive, and UNLOXCYT may face challenges from existing and new therapies.
• The document contains forward-looking statements that are subject to various risks and uncertainties.

Future Outlook

The transaction is expected to be completed in the second calendar quarter of 2025, subject to customary closing conditions, including required regulatory approvals and approval by Checkpoint's stockholders.

Management Comments

• Dilip Shanghvi, Chairman & Managing Director of Sun Pharma, said, 'Combining UNLOXCYT, an FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, with Sun Pharmas global presence means patients with cSCC may soon have access to an important, new treatment option. The acquisition further bolsters our innovative portfolio in onco-derm therapy.'
• James Oliviero, President and Chief Executive Officer of Checkpoint, said, 'Sun Pharma is aligned with Checkpoints commitment to improving the lives of skin cancer patients, and I believe this transaction will maximize value for our stockholders and provide accelerated access to UNLOXCYT in the United States, Europe and other markets worldwide.'

Industry Context

The acquisition allows Sun Pharma to expand its presence in the growing onco-dermatology market and leverage its global infrastructure to commercialize UNLOXCYT, a novel treatment for cSCC.

Comparison to Industry Standards

• The upfront cash payment of $4.10 per share represents a premium of approximately 66.0% to Checkpoints closing share price on March 7, 2025.
• The total transaction value of up to $416 million is a significant investment in a commercial-stage company with an FDA-approved product.
• Comparable companies in the pharmaceutical industry often trade at multiples of revenue or earnings, but Checkpoint's current financial performance makes such comparisons difficult.
• The CVR structure is a common mechanism in pharmaceutical acquisitions to share the risk and reward associated with future regulatory milestones.
• The royalty agreement with Fortress Biotech is a unique aspect of the transaction, reflecting the company's history and relationship with its controlling stockholder.

Corporate Governance

Related Party Transactions

• Fortress Biotech, Checkpoint's controlling stockholder, has entered into a royalty agreement with Sun Pharma and Checkpoint, under which Fortress would be entitled to receive royalty payments based on future sales of cosibelimab during a specified term, in lieu of royalty rights that were granted to Fortress in connection with its founding of Checkpoint.

Stakeholder Impact

• Checkpoint stockholders will receive a significant premium for their shares.
• Sun Pharma may be able to provide accelerated access to UNLOXCYT for patients in the United States, Europe, and other markets worldwide.
• Checkpoint employees may benefit from being part of a larger, more established organization.
• Fortress Biotech will receive royalty payments based on future sales of cosibelimab.

Next Steps

• Checkpoint will file a preliminary and definitive proxy statement with the SEC.
• Checkpoint will hold a special meeting of stockholders to approve the transaction.
• The parties will seek required regulatory approvals.
• The transaction is expected to close in the second calendar quarter of 2025.

Key Dates

Keywords

Checkpoint Therapeutics, Sun Pharma, acquisition, UNLOXCYT, cosibelimab, cutaneous squamous cell carcinoma, immuno-oncology, Fortress Biotech, merger, pharmaceuticals